logo
Select company
Select metric
$ -38.37MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
15
Sector
39
Industry
54
History
74
$ 7.67Close
$ 4.25 - $ 27.58 52-Week Range
Ticker Information

Ticker

LYRA

Company Name

LYRA THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

LYRA THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

LYRA - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 445K$ -38.82M$ -38.37M
3/31/2025$ 463K$ -79.5M$ -79.04M
12/31/2024$ 471K$ -93.4M$ -92.92M
9/30/2024$ 405K$ -97.56M$ -97.16M
6/30/2024$ 298K$ -101.33M$ -101.03M
3/31/2024$ 130K$ -68.82M$ -68.69M
12/31/2023$ 278K$ -62.62M$ -62.34M
9/30/2023$ 415K$ -61.7M$ -61.29M
6/30/2023$ 762K$ -60.84M$ -60.07M
3/31/2023$ 1.07M$ -59.59M$ -58.52M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • LYRA THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -22.03M.
  • Over the past 5 years, LYRA THERAPEUTICS INC's average EBITDA has been $ -56.4M.
  • The median EBITDA for LYRA THERAPEUTICS INC during this period was $ -54.2M
  • LYRA THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ -22.03M.
  • The lowest EBITDA recorded by LYRA THERAPEUTICS INC in the same timeframe $ -101.03M

LYRA THERAPEUTICS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
APRE : APREA THERAPEUTICS INC $ -14.83MBRTX : BIORESTORATIVE THERAPIES INC $ -10.44MERNA : ERNEXA THERAPEUTICS INC $ -37.86MVYNE : VYNE THERAPEUTICS INC $ -38.52MSXTP : 60 DEGREES PHARMACEUTICALS INC $ -7.74MLEXX : LEXARIA BIOSCIENCE CORP $ -11.27MICU : SEASTAR MEDICAL HOLDING CORP $ -14.63MRLYB : RALLYBIO CORP $ -41.54MIBIO : IBIO INC $ -17.04MCODX : CO-DIAGNOSTICS INC $ -34.67M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for LYRA THERAPEUTICS INC is calculated as follows: EBIT [ $ -22.13M ] + DepAmor [ $ 95K ]
(=) EBITDA [ $ -22.03M ]

LYRA - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -101.03M

Minimum

Jun 30, 2024

$ -22.03M

Maximum

Dec 31, 2020

$ -56.4M

Average

$ -54.2M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.9M with a standard deviation of $ 167.01M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.24K
min$ -493.3M
max$ 590.6M
average$ 58.9M
median$ 8.92M
std$ 167.01M